Global Opportunities. Local Focus.
Connecting Angel Investors with Innovative Entrepreneurs.
8TH ANNUAL INVESTOR CAPITAL EXPO
Keiretsu Forum Mid-Atlantic announces the 8th annual Mid-Atlantic Region Investor Capital Expo – Wednesday, October 14 at The Union League of Philadelphia.
SAVARA RINGS NASDAQ OPENING BELL!
Savara, a Keiretsu Forum Mid-Atlantic portfolio company, rang the opening bell on the Nasdaq Monday, July 23. Savara (SVRA) is the first Keiretsu Forum portfolio company to do so!
SALARIUS PHARMA LISTED ON NASDAQ
Salarius Pharmaceuticals (SLRX) opens trading on the NASDQ
Why Keiretsu Forum Mid-Atlantic?
“Keiretsu” is the Japanese word for a family of affiliated companies that form a tight-knit alliance and work toward each other’s mutual success. Consistent with this definition, Keiretsu Forum is a conglomeration of serious investors, business leaders, venture capitalists, corporate/institutional investors and serial entrepreneurs bound by two overlapping and codependent goals:
- To work together for each other’s mutual benefit, forming strategic partnerships, enhancing each other’s knowledge and building an angel network of diverse skills
- To access promising angel investment opportunities around the world
With more than 3,000 accredited angel investor members dispersed throughout 52 chapters on four continents, Keiretsu Forum is the world’s largest and most successful accredited investor – private equity community. Since Keiretsu Forum’s founding in 2000, its members have invested more than $1 billion in 950+ different companies from a myriad of industries, including software, telecommunications, health/life sciences, biotech, real estate, mobile applications, Internet, consumer products and other high growth areas.
LEARN MORE ABOUT KEIRETSU FORUM
“Keiretsu Forum takes a disciplined and comprehensive approach to deal screening and due diligence for their investors. Their process allows companies to access a large group of sophisticated investors, while allowing Keiretsu members to access quality deals. The enthusiasm Savara received has been tremendous; allowing us to proceed with a Phase II clinical trial in MRSA infected cystic fibrosis patients without the need for VC funding! With Keiretsu Forum’s chapters taking the lead, Savara raised over $39m from angel investors!”
Rob Neville CEO, Savara Pharmaceuticals, Inc.
© 2021 Web Design by RC: 